Literature DB >> 30577249

Hyaluronic Acid Is a Biomarker for Allograft Dysfunction and Predicts 1-Year Graft Loss After Liver Transplantation.

A A Rostved1, S R Ostrowski2, L Peters3, J D Lundgren3, J Hillingsø4, P I Johansson2, A Rasmussen4.   

Abstract

BACKGROUND: Allograft dysfunction after liver transplantation has a profound impact on the risks of death and retransplantation within the first year. We tested whether elevated hyaluronic acid (HA; a glycosaminoglycan cleared by hepatic sinusoidal endothelium) levels may predict excess risk of graft loss.
METHODS: This was a retrospective single-center prognostic cohort study. Patients with either a plasma sample before transplantation, an early post-transplantation sample nearest day 30 (range 10-89 d, 80% within days 15-60), or both were included. Plasma HA was measured with the use of enzyme-linked immunosorbent assays. The primary end point was 1-year graft loss (all-cause mortality and retransplantation). A secondary end point was biliary stricture.
RESULTS: In this study, 169 of 196 patients who received a liver transplant in the study period were included. Pre-transplantation HA (n = 152) did not predict graft loss. Post-transplantation HA (n = 124) was higher among patients with graft loss (median, 177 μg/L [interquartile range (IQR), 89-465] vs 54 μg/L [IQR 37-93]) and was a strong predictor of this outcome (hazard ratio per 50 μg/L, 1.24 [95% confidence interval [CI], 1.14-1.34]). The discriminatory ability of HA was high (area under the receiver operating characteristic curve, 0.86 [95% CI, 0.77-0.94]) and noninferior to other liver function tests. When adjusted for known risk factors of graft loss, HA remained an independent predictor of graft loss.
CONCLUSIONS: High post-transplantation plasma HA level was a strong predictor of 1-year all-cause mortality and retransplantation, whereas pre-transplantation levels were not, despite variety in the time span of blood sampling. Prospective studies are warranted to assess the utility of HA in liver transplantation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30577249     DOI: 10.1016/j.transproceed.2018.09.018

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Liver impairment in critical illness and sepsis: the dawn of new biomarkers?

Authors:  Martin Kluge; Frank Tacke
Journal:  Ann Transl Med       Date:  2019-12

2.  Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: its implication of posttransplant small-for-size syndrome.

Authors:  Hideaki Uchiyama; Ken Shirabe; Yuki Bekki; Takeo Toshima; Norifumi Harimoto; Toru Ikegami; Tomoharu Yoshizumi
Journal:  Transl Gastroenterol Hepatol       Date:  2019-05-25

Review 3.  Hyaluronan, a double-edged sword in kidney diseases.

Authors:  Aditya Kaul; Kavya L Singampalli; Umang M Parikh; Ling Yu; Sundeep G Keswani; Xinyi Wang
Journal:  Pediatr Nephrol       Date:  2021-05-19       Impact factor: 3.651

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.